Companies House 2025-02-01 2026-01-31 2026-01-31 false true iso4217:GBP xbrli:pure 09964076 2024-02-01 2025-01-31 09964076 2026-01-31 09964076 2025-02-01 2026-01-31 09964076 2025-01-31 09964076 curr:PoundSterling 2025-02-01 2026-01-31 09964076 uk-bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 09964076 uk-bus:FRS102 2025-02-01 2026-01-31 09964076 uk-bus:AuditExempt-NoAccountantsReport 2025-02-01 2026-01-31 09964076 uk-bus:AbridgedAccounts 2025-02-01 2026-01-31 09964076 uk-bus:RegisteredOffice 2025-02-01 2026-01-31 09964076 uk-bus:Director40 2025-02-01 2026-01-31 09964076 uk-bus:Director1 2025-02-01 2026-01-31 09964076 uk-bus:Director2 2025-02-01 2026-01-31 09964076 uk-bus:Director3 2025-02-01 2026-01-31 09964076 uk-bus:Director4 2025-02-01 2026-01-31 09964076 uk-bus:Director5 2025-02-01 2026-01-31 09964076 uk-bus:Director6 2025-02-01 2026-01-31 09964076 uk-bus:Director7 2025-02-01 2026-01-31 09964076 uk-bus:Director8 2025-02-01 2026-01-31 09964076 uk-bus:Director9 2025-02-01 2026-01-31 09964076 uk-bus:Director10 2025-02-01 2026-01-31 09964076 uk-bus:Director11 2025-02-01 2026-01-31 09964076 uk-bus:Director12 2025-02-01 2026-01-31 09964076 uk-bus:Director13 2025-02-01 2026-01-31 09964076 uk-bus:Director14 2025-02-01 2026-01-31 09964076 uk-bus:Director15 2025-02-01 2026-01-31 09964076 uk-bus:Director16 2025-02-01 2026-01-31 09964076 uk-bus:Director17 2025-02-01 2026-01-31 09964076 uk-bus:Director18 2025-02-01 2026-01-31 09964076 uk-bus:Director19 2025-02-01 2026-01-31 09964076 uk-bus:Director20 2025-02-01 2026-01-31 09964076 uk-bus:CompanySecretary1 2025-02-01 2026-01-31 09964076 core:AfterOneYear 2026-01-31 09964076 core:AfterOneYear 2025-01-31 09964076 core:WithinOneYear 2026-01-31 09964076 core:WithinOneYear 2025-01-31 09964076 core:WithinOneYear 2025-02-01 2026-01-31 09964076 core:AfterOneYear 2026-01-31 09964076 core:AfterOneYear 2025-01-31 09964076 core:AfterOneYear 2025-02-01 2026-01-31 09964076 core:ShareCapital 2026-01-31 09964076 core:ShareCapital 2025-01-31 09964076 core:SharePremium 2026-01-31 09964076 core:SharePremium 2025-01-31 09964076 core:OtherReservesSubtotal 2026-01-31 09964076 core:OtherReservesSubtotal 2025-01-31 09964076 core:RevaluationReserve 2026-01-31 09964076 core:RevaluationReserve 2025-01-31 09964076 core:RetainedEarningsAccumulatedLosses 2026-01-31 09964076 core:RetainedEarningsAccumulatedLosses 2025-01-31 09964076 core:Associate1 2025-02-01 2026-01-31 09964076 core:Associate1 2025-01-31 09964076 core:Associate1 2026-01-31 09964076 core:Associate2 2025-02-01 2026-01-31 09964076 core:Associate2 2025-01-31 09964076 core:Associate2 2026-01-31 09964076 core:Associate3 2025-02-01 2026-01-31 09964076 core:Associate3 2025-01-31 09964076 core:Associate3 2026-01-31 09964076 core:Associate4 2025-02-01 2026-01-31 09964076 core:Associate4 2025-01-31 09964076 core:Associate4 2026-01-31 09964076 core:Associate5 2025-02-01 2026-01-31 09964076 core:Associate5 2025-01-31 09964076 core:Associate5 2026-01-31 09964076 core:Associate6 2025-02-01 2026-01-31 09964076 core:Associate6 2025-01-31 09964076 core:Associate6 2026-01-31 09964076 core:Associate7 2025-02-01 2026-01-31 09964076 core:Associate7 2025-01-31 09964076 core:Associate7 2026-01-31 09964076 core:Associate8 2025-02-01 2026-01-31 09964076 core:Associate8 2025-01-31 09964076 core:Associate8 2026-01-31 09964076 core:Associate9 2025-02-01 2026-01-31 09964076 core:Associate9 2025-01-31 09964076 core:Associate9 2026-01-31 09964076 core:Associate10 2025-02-01 2026-01-31 09964076 core:Associate10 2025-01-31 09964076 core:Associate10 2026-01-31 09964076 core:Associate11 2025-02-01 2026-01-31 09964076 core:Associate11 2025-01-31 09964076 core:Associate11 2026-01-31 09964076 core:Associate12 2025-02-01 2026-01-31 09964076 core:Associate12 2025-01-31 09964076 core:Associate12 2026-01-31 09964076 core:Associate13 2025-02-01 2026-01-31 09964076 core:Associate13 2025-01-31 09964076 core:Associate13 2026-01-31 09964076 core:Associate14 2025-02-01 2026-01-31 09964076 core:Associate14 2025-01-31 09964076 core:Associate14 2026-01-31 09964076 core:Associate15 2025-02-01 2026-01-31 09964076 core:Associate15 2025-01-31 09964076 core:Associate15 2026-01-31 09964076 core:Associate16 2025-02-01 2026-01-31 09964076 core:Associate16 2025-01-31 09964076 core:Associate16 2026-01-31 09964076 core:Associate17 2025-02-01 2026-01-31 09964076 core:Associate17 2025-01-31 09964076 core:Associate17 2026-01-31 09964076 core:Associate18 2025-02-01 2026-01-31 09964076 core:Associate18 2025-01-31 09964076 core:Associate18 2026-01-31 09964076 core:Associate19 2025-02-01 2026-01-31 09964076 core:Associate19 2025-01-31 09964076 core:Associate19 2026-01-31 09964076 core:Associate20 2025-02-01 2026-01-31 09964076 core:Associate20 2025-01-31 09964076 core:Associate20 2026-01-31 09964076 core:Associate1 2025-02-01 2026-01-31 09964076 core:Associate2 2025-02-01 2026-01-31 09964076 core:Associate3 2025-02-01 2026-01-31 09964076 core:Associate4 2025-02-01 2026-01-31 09964076 core:Associate5 2025-02-01 2026-01-31 09964076 core:Associate6 2025-02-01 2026-01-31 09964076 core:Associate7 2025-02-01 2026-01-31 09964076 core:Associate8 2025-02-01 2026-01-31 09964076 core:Associate9 2025-02-01 2026-01-31 09964076 core:Associate10 2025-02-01 2026-01-31 09964076 core:Associate11 2025-02-01 2026-01-31 09964076 core:Associate12 2025-02-01 2026-01-31 09964076 core:Associate13 2025-02-01 2026-01-31 09964076 core:Associate14 2025-02-01 2026-01-31 09964076 core:Associate15 2025-02-01 2026-01-31 09964076 core:Associate16 2025-02-01 2026-01-31 09964076 core:Associate17 2025-02-01 2026-01-31 09964076 core:Associate18 2025-02-01 2026-01-31 09964076 core:Associate19 2025-02-01 2026-01-31 09964076 core:Associate20 2025-02-01 2026-01-31 09964076 uk-bus:Director1 1 2025-02-01 2026-01-31 09964076 uk-bus:Director1 1 2025-01-31 09964076 uk-bus:Director1 1 2026-01-31 09964076 uk-bus:Director2 2 2025-02-01 2026-01-31 09964076 uk-bus:Director2 2 2025-01-31 09964076 uk-bus:Director2 2 2026-01-31 09964076 uk-bus:Director1 3 2025-02-01 2026-01-31 09964076 uk-bus:Director1 3 2025-01-31 09964076 uk-bus:Director1 3 2026-01-31 09964076 uk-bus:Director4 4 2025-02-01 2026-01-31 09964076 uk-bus:Director4 4 2025-01-31 09964076 uk-bus:Director4 4 2026-01-31 09964076 uk-bus:Director5 5 2025-02-01 2026-01-31 09964076 uk-bus:Director5 5 2025-01-31 09964076 uk-bus:Director5 5 2026-01-31 09964076 uk-bus:Director6 6 2025-02-01 2026-01-31 09964076 uk-bus:Director6 6 2025-01-31 09964076 uk-bus:Director6 6 2026-01-31 09964076 uk-bus:Director7 7 2025-02-01 2026-01-31 09964076 uk-bus:Director7 7 2025-01-31 09964076 uk-bus:Director7 7 2026-01-31 09964076 uk-bus:Director8 8 2025-02-01 2026-01-31 09964076 uk-bus:Director8 8 2025-01-31 09964076 uk-bus:Director8 8 2026-01-31 09964076 uk-bus:Director9 9 2025-02-01 2026-01-31 09964076 uk-bus:Director9 9 2025-01-31 09964076 uk-bus:Director9 9 2026-01-31 09964076 uk-bus:Director10 10 2025-02-01 2026-01-31 09964076 uk-bus:Director10 10 2025-01-31 09964076 uk-bus:Director10 10 2026-01-31 09964076 uk-bus:Director11 11 2025-02-01 2026-01-31 09964076 uk-bus:Director11 11 2025-01-31 09964076 uk-bus:Director11 11 2026-01-31 09964076 uk-bus:Director12 12 2025-02-01 2026-01-31 09964076 uk-bus:Director12 12 2025-01-31 09964076 uk-bus:Director12 12 2026-01-31 09964076 uk-bus:Director13 13 2025-02-01 2026-01-31 09964076 uk-bus:Director13 13 2025-01-31 09964076 uk-bus:Director13 13 2026-01-31 09964076 uk-bus:Director14 14 2025-02-01 2026-01-31 09964076 uk-bus:Director14 14 2025-01-31 09964076 uk-bus:Director14 14 2026-01-31 09964076 uk-bus:Director15 15 2025-02-01 2026-01-31 09964076 uk-bus:Director15 15 2025-01-31 09964076 uk-bus:Director15 15 2026-01-31 09964076 uk-bus:Director16 16 2025-02-01 2026-01-31 09964076 uk-bus:Director16 16 2025-01-31 09964076 uk-bus:Director16 16 2026-01-31 09964076 uk-bus:Director17 17 2025-02-01 2026-01-31 09964076 uk-bus:Director17 17 2025-01-31 09964076 uk-bus:Director17 17 2026-01-31 09964076 uk-bus:Director18 18 2025-02-01 2026-01-31 09964076 uk-bus:Director18 18 2025-01-31 09964076 uk-bus:Director18 18 2026-01-31 09964076 uk-bus:Director19 19 2025-02-01 2026-01-31 09964076 uk-bus:Director19 19 2025-01-31 09964076 uk-bus:Director19 19 2026-01-31 09964076 uk-bus:Director20 20 2025-02-01 2026-01-31 09964076 uk-bus:Director20 20 2025-01-31 09964076 uk-bus:Director20 20 2026-01-31 09964076 1 2025-02-01 2026-01-31 09964076 2 2025-02-01 2026-01-31 09964076 3 2025-02-01 2026-01-31

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Company Registration Number:
09964076 (England and Wales)

## Unaudited abridged accounts for the year ended 31 January 2026

## Period of accounts

## Start date: 01 February 2025

## End date: 31 January 2026

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Contents of the Financial Statements

for the Period Ended 31 January 2026

Balance sheet |
Notes |

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Balance sheet

As at 31 January 2026

| Notes | 2026 | 2025
--- | --- | --- | ---
|  | £ | £
Fixed assets
Tangible assets: | 3 | 26,486 | 24,678
Total fixed assets: |  | 26,486 | 24,678
Current assets
Debtors: |  | 84,970 | 53,879
Cash at bank and in hand: |  | 4,250,497 | 3,730,546
Total current assets: |  | 4,335,467 | 3,784,425
Creditors: amounts falling due within one year: |  | (253,624) | (227,390)
Net current assets (liabilities): |  | 4,081,843 | 3,557,035
Total assets less current liabilities: |  | 4,108,329 | 3,581,713
Provision for liabilities: |  | (6,621) | (6,170)
Total net assets (liabilities): |  | 4,101,708 | 3,575,543
Capital and reserves
Called up share capital: |  | 150 | 150
Profit and loss account: |  | 4,101,558 | 3,575,393
Shareholders funds: |  | 4,101,708 | 3,575,543

The notes form part of these financial statements

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Balance sheet statements

For the year ending 31 January 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 20 May 2026
and signed on behalf of the board by:

Name: Mr EPL Turton
Status: Director

The notes form part of these financial statements

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 January 2026

## 1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

## Turnover policy

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes.

## Tangible fixed assets and depreciation policy

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter. Plant and machinery etc.: Plant and machinery - 25% reducing balance

## Other accounting policies

Taxation Taxation for the year comprises current and deferred taxation. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current or deferred taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred taxation Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that been enacted or substantively enacted by the balance sheet date and that are expected to apply to the reversal of the timing difference. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probably that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 January 2026

## 2. Employees

| 2026 | 2025
--- | --- | ---
Average number of employees during the period | 2 | 2

# LEEDS BREAST AND COSMETIC CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 January 2026

## 3. Tangible Assets

| Total
--- | ---
Cost | £
At 01 February 2025 | 99,197
Additions | 10,637
At 31 January 2026 | 109,834
Depreciation |
At 01 February 2025 | 74,519
Charge for year | 8,829
At 31 January 2026 | 83,348
Net book value |
At 31 January 2026 | 26,486
At 31 January 2025 | 24,678